September 2014

Our coverage of the 15th Annual International Lung Cancer Congress, which Physicians' Education Resource (PER) hosted July 31-August 2 in California, illustrates how nuanced genomic targeting has become in NSCLC.

For more than 20 years, Klaus Strebhardt, PhD, has been exploring the polo-like kinase (PLK) pathway, including its role in cancer and Plk1-targeted anticancer therapies.

The concept of targeting mitotic cell division to halt the progression of rapidly dividing cancer cells has long been a staple of oncology therapy, yet chemotherapy agents that are the prime examples of this approach are nonselective in their action and can kill normal and malignant cells alike.

Although the incidence and mortality of prostate cancer remain formidable problems in the United States, clinicians have many new agents with proven overall survival (OS) benefits to recommend for patients with metastatic disease.

At the 2014 ASCO meeting, OncologyLive sat down with Jimmie C. Holland, MD, the Wayne E. Chapman Chair in Psychiatric Oncology at Memorial Sloan Kettering Cancer Center and the recipient of the 2014 Giants of Cancer Careâ„¢ Award for her pioneering contributions in the field of supportive care.

Although universal insurance coverage for postmastectomy breast reconstruction has been mandated since 1998, a new study has found that the persistently high rates of American women who choose not to undergo reconstruction surgery are due primarily to patient preferences and not a lack of awareness.

Myeloma survivors owe much to Robert A. Kyle's reluctance to perform autopsies or to undergo cardiac catheterization.

The Hispanic population in the United States represents the fastest-growing segment of the population (expected to reach 30% of the nation's total by 2050), and faces significant cancer health disparities

Approximately 85% of patients with newly diagnosed melanoma present with what appears to be clinically localized disease, making them candidates for standard treatment with surgery.

Oncologists Need Guideposts for Recommending Drugs Not Studied in Cancers

How can a conscientious but very busy practitioner keep up with the massive quantity of molecular data that could potentially impact an individual patient with cancer? The Moores Cancer Center at the University of California, San Diego has updated the tumor board concept for the molecular era.